Medicine and Dentistry
Gynecological Oncology
100%
Ovarian Cancer
85%
Endometrial Cancer
66%
Disease
58%
Neoplasm
57%
Endometrium Carcinoma
45%
Malignant Neoplasm
43%
Overall Survival
43%
Fallopian Tube
41%
Female Genital Tract Cancer
41%
Hysterectomy
39%
Transgender
36%
Bevacizumab
36%
Venous Thromboembolism
36%
Intracavitary Brachytherapy
36%
Uterine Serous Carcinoma
36%
Hazard Ratio
35%
Krukenberg Tumor
31%
Carboplatin
29%
Breast Cancer
24%
Bleeding
24%
Dysplasia
24%
Cisplatin
21%
Leiomyosarcoma
21%
Clinical Guideline
21%
Recurrent Disease
20%
Oncology
20%
Clinical Trial
19%
Progression Free Survival
19%
Epithelial Cell
18%
Gene Expression
18%
Drug Response
18%
Cervical Cancer Prevention
18%
Ascites
18%
Gamma Urogastrone
18%
Program Director
18%
Uterus Sarcoma
18%
Cancer Epidemiology
18%
Desensitization
18%
Peritoneum Cancer
18%
Methylated DNA Protein Cysteine Methyltransferase
18%
Gynecological Surgery
18%
Carbon Dioxide Laser
18%
Endometrial Intraepithelial Neoplasia
18%
Laser Surgery
18%
Gastrointestinal Cancer
18%
Drug Megadose
18%
Incisional Hernia
18%
Temozolomide
18%
Hypersensitivity
18%
Keyphrases
Ovarian Cancer
64%
Endometrial Cancer
59%
Gynecologic Oncology
42%
Gynecological Cancer
41%
Transgender
36%
Bevacizumab
36%
Venous Thromboembolism
36%
Uterine Serous Carcinoma
36%
Endometrial Intraepithelial Neoplasia
36%
Willingness to Participate
36%
Randomized Trial
33%
Overall Survival
31%
Complete Response
30%
Uterus
25%
Breast Cancer
24%
Clinical Trials
23%
Histological Subtypes
22%
Willingness to Participate in Clinical Trials
22%
Advanced Ovarian Cancer
21%
Human Epidermal Growth Factor Receptor 2 (HER2)
21%
Endometrial Carcinoma
21%
Survival Prediction
20%
Fallopian Tube Cancer
20%
Resource Needs
18%
Adherence to Clinical Guidelines
18%
Quality Improvement Project
18%
Cancer Guidelines
18%
Gender Diverse
18%
Patient Perception
18%
Putative Drug Targets
18%
Drug Response
18%
Cancer Surveillance
18%
Frontline Therapy
18%
Ascites
18%
Ovarian Carcinoma
18%
Cavernous Hemangioma
18%
Diverse Patients
18%
Live Birth Rate
18%
Peritoneal Cancer
18%
Gastrointestinal Cancer
18%
Social Resources
18%
Multigene Expression
18%
Patient Benefit
18%
Novel Treatments
18%
Medical Comorbidity
18%
Journal Club
18%
Never Events
18%
Minimally Invasive Gynecologic Surgery
18%
Treatment of Women
18%
O6-methylguanine-DNA Methyltransferase
18%